Antiviral effect of raltegravir on HTLV-1 carriers (Q39533380)

12 September 2017

Antiviral effect of raltegravir on HTLV-1 carriers (English)

1 reference

Human T-lymphotropic virus 1

12 September 2017

0 references

1 reference

6

Vincent Soriano

1 reference

12 September 2017

Ana Treviño

1

1 reference

12 September 2017

Patricia Parra

2

1 reference

12 September 2017

Tamara Bar-Magen

3

1 reference

12 September 2017

Carolina Garrido

4

1 reference

12 September 2017

Carmen de Mendoza

5

1 reference

12 September 2017

language of work or name

English

0 references

publication date

29 September 2011

1 reference

Journal of Antimicrobial Chemotherapy

12 September 2017

1 reference

12 September 2017

67

1 reference

12 September 2017

218-221

1 reference

12 September 2017

1

1 reference

Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera

12 September 2017

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR404

Relationship between human T lymphotropic virus (HTLV) type 1/2 viral burden and clinical and treatment parameters among patients with HIV type 1 and HTLV-1/2 coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR404

High-dose zidovudine induction in HTLV-I-associated myelopathy: safety and possible efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR404

Effects of nucleoside-based antiretroviral chemotherapy on human T cell leukaemia/lymphotropic virus type 1 (HTLV-1) infection in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR404

Drug targets in human T-lymphotropic virus type 1 (HTLV-1) infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR404

Integrase inhibitors effective against human T-cell leukemia virus type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR404

Prevalence of HTLV-1/2 infections in Spain: A cross-sectional hospital-based survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR404

Evaluation of the use of real-time PCR for human T cell lymphotropic virus 1 and 2 as a confirmatory test in screening for blood donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR404

The effect of zidovudine on chronic myelopathy associated with HTLV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR404

Zidovudine plus lamivudine in Human T-Lymphotropic Virus type-I-associated myelopathy: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR404

Pharmacological inhibition of in vitro infectivity of human T lymphotropic virus type I

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR404

The immune control and cell-to-cell spread of human T-lymphotropic virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR404

Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR404

Nonspecific integration of the HTLV provirus genome into adult T-cell leukaemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR404

Corticosteroid therapy in TSP/HAM patients: the results from a 10 years open cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR404

Tropical Spastic Paraparesis/HTLV-1-Associated Myelopathy (TSP/HAM): Treatment with an Anabolic Steroid Danazol

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR404

Successful application of pentoxifylline in the treatment of HTLV-I associated myelopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR404

Interferon-alpha is effective in HTLV-I-associated myelopathy: a multicenter, randomized, double-blind, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR404

Long-term, high dose interferon-alpha treatment in HTLV-I-associated myelopathy/tropical spastic paraparesis: a combined clinical, virological and immunological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR404

Decreased human T lymphotropic virus type I (HTLV-I) provirus load and alteration in T cell phenotype after interferon-alpha therapy for HTLV-I-associated myelopathy/tropical spastic paraparesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR404

The effect of antiretroviral therapy on HTLV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR404

Histone deacetylase mediated transcriptional activation reduces proviral loads in HTLV-1 associated myelopathy/tropical spastic paraparesis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR404

Highly active antiretroviral treatment against STLV-1 infection combining reverse transcriptase and HDAC inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR404

Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR404

21 January 2018

Identifiers

DOI

10.1093/JAC/DKR404

1 reference

12 September 2017

1 reference